In short
PF-07275315 is an investigational protein-based substance being studied in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD). It has no marketing authorisation and is given as a subcutaneous injection. One authorised Phase 2/3 trial (2024-518587-12-00) is evaluating it in 1,056 participants.
Key points
- PF-07275315 is a protein-based investigational substance for COPD.
- It is given by subcutaneous injection.
- The registered trial is Phase 2/3 and plans to enrol 1,056 participants.
- The trial compares two doses of PF-07275315 with placebo.
- Key outcomes include lung function (FEV1) and the rate of COPD flare-ups.
- PF-07275315 has no marketing authorisation in the product records.
What is PF-07275315?
PF-07275315 is a protein-based investigational substance being developed for adults with moderate-to-severe chronic obstructive pulmonary disease (COPD). It is supplied by Pfizer Inc. and has no marketing authorisation in the product records, meaning it is not yet an approved medicine. The substance appears as the test product in one registered clinical trial.
How does PF-07275315 work?
The registry records do not describe the molecular target or mechanism of action of PF-07275315. It is classified in the therapeutic area of respiratory tract diseases. The trial is designed to assess whether the substance can improve lung function and reduce COPD flare-ups compared with placebo.
Which conditions is PF-07275315 studied for?
- Moderate-to-severe chronic obstructive pulmonary disease (COPD) — a long-term breathing difficulty. The trial studies PF-07275315 in adults with this condition.
How is PF-07275315 given?
PF-07275315 is prepared as a solution for injection and given by subcutaneous injection, which means it is injected under the skin. The registry record does not report the dose, because the dose is listed as 0 mg, meaning the dose was not reported.
What do the clinical trials show?
One trial is registered for PF-07275315: EU CT number 2024-518587-12-00, currently authorised. It is a Phase 2/3 interventional study planning to enrol 1,056 participants with moderate-to-severe COPD. The Phase 2 part assesses two doses of PF-07275315 compared with placebo, while the Phase 3 part assesses efficacy compared with placebo.
The primary outcomes differ by phase. In Phase 2, the main measure is the change from baseline in pre-bronchodilator forced expiratory volume in one second (FEV1) at Week 24 compared with placebo; FEV1 is how much air a person can force out in one second. In Phase 3, the main measure is the annualised rate of moderate or severe COPD exacerbations (ECOPD), meaning how many flare-ups occur per year.
What side effects are known?
No side effect information is available in the registry data or supplementary sources for PF-07275315.
